427 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
of spend and the impact of recent acquisitions.
On a GAAP basis, research and development expenses increased 16% to $2.7 billion and on a non-GAAP … expenses and research and development expenses excluding certain specified items as a percentage of revenues, non-GAAP operating expenses, which
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
the net impact of Acquired IPRD charges and licensing income of ($0.28) in 2023. Acquired IPRD refers to certain in-process research and development
8-K
EX-99.1
w213 srf0s9
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
8-K
EX-99.1
qut1c0
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
pny4j zy4l
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
dwqxgrggoun47
8 Jan 24
Regulation FD Disclosure
10:29am
8-K
EX-99.2
awor7ka
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
26ah2xrou1 e8b
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
g1hb9d4f4vbr3s
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.2
w1sfeku dh6bttoqpah4
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
dt74t
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
DEFA14A
dohb q4kb
10 Apr 23
Additional proxy soliciting materials
5:12pm